Yuen Shing is best known for his techniques for purification and characterization of angiogenesis stimulators and inhibitors. These techniques were emulated by Michael O'Reilly, who discovered angiostatin and endostatin, and by other scientists around the world. In 1984, Shing, along with Michael Klagsbrun, achieved the first complete purification of a tumor-derived angiogenic endothelial growth factor. The factor turned out to be identical to fibroblast growth factor (FGF). Shing also discovered betacellulin, a novel protein that stimulates growth of smooth muscles in blood vessels and is an amplifier of angiogenesis.
About Yuen Shing
Shing received a doctorate in biochemistry from the University of Kansas. Following post-doctoral training at the State University of New York and University of Wisconsin, he was appointed Assistant Professor at the University of Massachusetts. He joined the Surgical Research Laboratories at Children's in 1980.
- Fang J, Yan L, Shing Y, Moses MA. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Research 2001; 61: 5731-5735.
- Beecken WD, Fernandez A, Joussen AM, Achilles EG, Flynn E, Lo KM, Gillies SD, Javaherian K, Folkman J, Shing Y. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. Journal of the National Cancer Institute 2001; 93: 382-387.
- Fang J, Shing Y, Wiederschain D. Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proceedings of the National Academy of Sciences USA 2000; 97: 3884-3889.